BACKGROUND: Transfusion therapy is frequently used to prevent morbidity in sickle cell disease (SCD), and subsequent iron overload is common. The objective of this study was to evaluate the current standard of care in monitoring iron overload and related complications in patients with SCD compared to thalassemia (Thal). STUDY DESIGN AND METHODS: A cross-sectional study was conducted at 31 hematology clinics in the United States, Canada, or the United Kingdom. Patients who received transfusions with a mean serum ferritin level of least 2000 ng per mL were eligible. A total of 199 patients with SCD (113 female; 24.9 +/- 13.2 years) and 142 with Thal (66 female; 25.8 +/- 8.1 years) were recruited, and data were collected between 2001 and 2003 by interview and medical record review. RESULTS: Although both groups were recruited on the basis of significant iron overload, the likelihood of performing a liver biopsy for routine iron monitoring was significantly higher (odds ratio [OR], 3.4; 95% confidence interval [CI], 2.2-5.3) in Thal than SCD. Thal patients were also more likely to be screened for iron-related organ injury including an echocardiograph for cardiomyopathy (OR, 2.6; p < 0.001; 95% CI, 1.6-4.2), alanine aminotransferase for liver function (OR, 8.3; CI, 1.05-64.4), and thyroid-stimulating hormone for hypothyroidism (OR, 12.3; CI, 7.0-21.5). For adult SCD patients, those maintained on simple transfusion with a serum ferritin level of greater than 2500 ng per mL were the least likely to have a liver biopsy (p < 0.03). CONCLUSIONS: These data highlight the unsystematic monitoring of iron and related organ injury in SCD. Until the relationship between iron and related comorbidities is better understood, routine monitoring of iron overload in SCD patients who receive transfusions should be considered a standard part of clinical care.
BACKGROUND: Transfusion therapy is frequently used to prevent morbidity in sickle cell disease (SCD), and subsequent iron overload is common. The objective of this study was to evaluate the current standard of care in monitoring iron overload and related complications in patients with SCD compared to thalassemia (Thal). STUDY DESIGN AND METHODS: A cross-sectional study was conducted at 31 hematology clinics in the United States, Canada, or the United Kingdom. Patients who received transfusions with a mean serum ferritin level of least 2000 ng per mL were eligible. A total of 199 patients with SCD (113 female; 24.9 +/- 13.2 years) and 142 with Thal (66 female; 25.8 +/- 8.1 years) were recruited, and data were collected between 2001 and 2003 by interview and medical record review. RESULTS: Although both groups were recruited on the basis of significant iron overload, the likelihood of performing a liver biopsy for routine iron monitoring was significantly higher (odds ratio [OR], 3.4; 95% confidence interval [CI], 2.2-5.3) in Thal than SCD. Thal patients were also more likely to be screened for iron-related organ injury including an echocardiograph for cardiomyopathy (OR, 2.6; p < 0.001; 95% CI, 1.6-4.2), alanine aminotransferase for liver function (OR, 8.3; CI, 1.05-64.4), and thyroid-stimulating hormone for hypothyroidism (OR, 12.3; CI, 7.0-21.5). For adult SCDpatients, those maintained on simple transfusion with a serum ferritin level of greater than 2500 ng per mL were the least likely to have a liver biopsy (p < 0.03). CONCLUSIONS: These data highlight the unsystematic monitoring of iron and related organ injury in SCD. Until the relationship between iron and related comorbidities is better understood, routine monitoring of iron overload in SCDpatients who receive transfusions should be considered a standard part of clinical care.
Authors: Elliott Vichinsky; Ellen Butensky; Ellen Fung; Mark Hudes; Elizabeth Theil; Linda Ferrell; Roger Williams; Leslie Louie; Phillip D K Lee; Paul Harmatz Journal: Am J Hematol Date: 2005-09 Impact factor: 10.047
Authors: P Pootrakul; K Kitcharoen; P Yansukon; P Wasi; S Fucharoen; P Charoenlarp; G Brittenham; M J Pippard; C A Finch Journal: Blood Date: 1988-04 Impact factor: 22.113
Authors: P Harmatz; E Butensky; K Quirolo; R Williams; L Ferrell; T Moyer; D Golden; L Neumayr; E Vichinsky Journal: Blood Date: 2000-07-01 Impact factor: 22.113
Authors: N F Olivieri; D G Nathan; J H MacMillan; A S Wayne; P P Liu; A McGee; M Martin; G Koren; A R Cohen Journal: N Engl J Med Date: 1994-09-01 Impact factor: 91.245
Authors: Anthony T W Cheung; Joshua W Miller; Maricel G Miguelino; Wilson J To; Jiajing Li; Xin Lin; Peter C Chen; Sandra L Samarron; Ted Wun; Theodore Zwerdling; Ralph Green Journal: J Pediatr Hematol Oncol Date: 2012-04 Impact factor: 1.289
Authors: John A Shepherd; Bo Fan; Ying Lu; Lorena Marquez; Khaled Salama; Jimmy Hwang; Ellen B Fung Journal: J Clin Densitom Date: 2010-07-21 Impact factor: 2.617
Authors: Mehdi Nouraie; Deepika S Darbari; Sohail Rana; Caterina P Minniti; Oswaldo L Castro; Lori Luchtman-Jones; Craig Sable; Niti Dham; Gregory J Kato; Mark T Gladwin; Gregory Ensing; Manuel Arteta; Andrew Campbell; James G Taylor; Sergei Nekhai; Victor R Gordeuk Journal: Am J Hematol Date: 2020-04-21 Impact factor: 10.047
Authors: Nilesh R Ghugre; Ignacio Gonzalez-Gomez; Ellen Butensky; Leila Noetzli; Roland Fischer; Roger Williams; Paul Harmatz; Thomas D Coates; John C Wood Journal: Am J Hematol Date: 2009-08 Impact factor: 10.047